Home » FDA Grants Novartis’ Tabrecta Accelerated Approval for Lung Cancer
FDA Grants Novartis’ Tabrecta Accelerated Approval for Lung Cancer
The FDA granted Novartis accelerated approval for Tabrecta (capmatinib) for treatment for adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
Tabrecta is the first FDA-approved therapy to treat NSCLC with specific mutations that can cause cancer metastasis, including those that lead to mesenchymal-epithelial transition (MET).
The drug received breakthrough therapy, priority review and orphan drug designations.
Upcoming Events
-
07May
-
14May
-
30May